𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Duloxetine in the treatment of binge eating disorder with depressive disorders: A placebo-controlled trial

✍ Scribed by Guerdjikova, Anna I. ;McElroy, Susan L. ;Winstanley, Erin L. ;Nelson, Eric B. ;Mori, Nicole ;McCoy, Jessica ;Keck, Paul E. ;Hudson, James I.

Publisher
Wiley (John Wiley & Sons)
Year
2011
Tongue
English
Weight
879 KB
Volume
45
Category
Article
ISSN
0276-3478

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective:

This study evaluated duloxetine in the treatment of binge eating disorder (BED) with comorbid current depressive disorders.

Method:

In this 12‐week, double‐blind, placebo‐controlled trial, 40 patients with Diagnostic and Statistical Manual of Mental Disorders‐IV‐TR BED and a comorbid current depressive disorder received duloxetine (N = 20) or placebo (N = 20). The primary outcome measure was weekly binge eating day frequency.

Results:

In the primary analysis, duloxetine (mean 78.7 mg/day) was superior to placebo in reducing weekly frequency of binge eating days (p = .04), binge eating episodes (p = .02), weight (p = .04), and Clinical Global Impression‐Severity of Illness ratings for binge eating (p = .02) and depressive disorders (p = .01). Changes in body mass index and measures of eating pathology, depression, and anxiety did not differ between the two groups.

Discussion:

Duloxetine may be effective for reducing binge eating, weight, and global severity of illness in BED with a comorbid current depressive disorder, but this finding needs confirmation in larger, placebo‐controlled trials. © 2011 by Wiley Periodicals, Inc. (Int J Eat Disord 2012)

📜 SIMILAR VOLUMES

High-dose escitalopram in the treatment
High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial
✍ Anna I. Guerdjikova; Susan L. McElroy; Renu Kotwal; Jeffrey A. Welge; Erik Nelso 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Abstract ## Objective The purpose of this study was to evaluate the efficacy and safety of high‐dose escitalopram in the treatment of binge‐eating disorder (BED) associated with obesity. ## Method Forty‐four outpatients with BED by DSM‐IV criteria and obesity were randomized to receive either

A double-blind, multicenter trial compar
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
✍ Lesley M. Arnold; Yili Lu; Leslie J. Crofford; Madelaine Wohlreich; Michael J. D 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 2 views

## Abstract ## Objective To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder. ## Methods This study was a randomized, double‐blind, placebo‐controlled trial co

Eating disorders and psychiatric disorde
Eating disorders and psychiatric disorders in the first-degree relatives of obese probands with binge eating disorder and obese non-binge eating disorder controls
✍ Lee, Young H. ;Abbott, David W. ;Seim, Harold ;Crosby, Ross D. ;Monson, Nancy ;B 📂 Article 📅 1999 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 130 KB 👁 3 views

## Objective: The purposes of the present study were to examine the possibility of a familial tendency for binge eating disorder (BED) among the obese, to clarify the relationship between BED and other eating disorders, and to test the relationship between BED and other psychiatric disorders. Meth

Safety and tolerability of duloxetine in
Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials
✍ James I. Hudson; Madelaine M. Wohlreich; Daniel K. Kajdasz; Craig H. Mallinckrod 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

## Abstract ## Objective To examine the safety and tolerability of the antidepressant duloxetine across multiple studies for major depressive disorder (MDD). ## Method Safety data were integrated from the acute phases of eight double‐blind, placebo‐controlled trials in which patients were random